Literature DB >> 2970686

Clearance of cryoglobulins in man.

Y C Ng1, J A Schifferli.   

Abstract

From the foregoing it is evident that the defective clearance of immune complexes may contribute to tissue damage seen in patients with cryoglobulins. Hypocomplementaemia, decreased erythrocyte CR1, and the nature of the immune complexes may all contribute to decreased binding of immune complexes to erythrocytes with the potential consequence of increased availability for deposition and decreased processing of immune complexes. In addition, in type II cryoglobulinaemia the nature of the immune complex namely IgM RF/IgG complexes, has been shown in some circumstances to fix C3 and C4 inefficiently in spite of detectable fluid phase complement activation. The poor C3 fixation results not only in decreased transport by erythrocytes to the RES but also in inefficient removal of immune complexes by phagocytic cells, since the Fc receptor on these cells would be acting alone without the synergy of occupied complement receptors. Persistence of immune complexes in tissues in these circumstances has two potential consequences. First, the multivalency of IgM may contribute to enlargement of these immune complexes in situ by successive trapping of antigen and antibody complexes; this process may be aided by local factors such as low temperature at the peripheries and increased protein concentration in glomerular capillary loops, which favour "cryo" precipitation. The higher avidity of RF for IgG that is surface bound rather than monomeric would also favor immune complex formation in these circumstances. Second, although there is no opsonization of the immune complex complement activation results in bystander fixation of C4 and C3 to the surrounding tissues resulting in tissue injury.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970686     DOI: 10.1007/bf02054025

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  83 in total

Review 1.  The biology and detection of immune complexes.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

2.  The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms.

Authors:  J A Schifferli; Y C Ng; J Estreicher; M J Walport
Journal:  J Immunol       Date:  1988-02-01       Impact factor: 5.422

Review 3.  The role of complement and its receptor in the elimination of immune complexes.

Authors:  J A Schifferli; Y C Ng; D K Peters
Journal:  N Engl J Med       Date:  1986-08-21       Impact factor: 91.245

4.  Cryoglobulins. I. Studies on the nature, incidence, and clinical significance of serum cryoproteins in glomerulonephritis.

Authors:  R M McIntosh; D B Kaufman; C Kulvinskas; B J Grossman
Journal:  J Lab Clin Med       Date:  1970-04

5.  The assembly of early components of complement on antibody-antigen aggregates and on antibody-coated erythrocytes.

Authors:  J W Goers; R R Porter
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

6.  The specificity and polyvalency of binding of a monoclonal rheumatoid factor.

Authors:  R Eisenberg
Journal:  Immunochemistry       Date:  1976-04

7.  Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.

Authors:  G Doekes; J Schouten; A Cats; M R Daha
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

8.  Increase in the complement-fixing ability of murine IgG anti-lymphocyte antibodies by addition of monoclonal IgM rheumatoid factors.

Authors:  D A Carson
Journal:  J Immunol Methods       Date:  1984-03-30       Impact factor: 2.303

9.  Rheumatoid factor inhibition of in vitro binding of IgG complexes in the human glomerulus.

Authors:  W K Bolton; J H Schrock; J S Davis
Journal:  Arthritis Rheum       Date:  1982-03

10.  Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis.

Authors:  C J Jaffe; J M Vierling; E A Jones; T J Lawley; M M Frank
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

View more
  2 in total

1.  Hepatitis C: a possible etiology for cryoglobulinaemia type II.

Authors:  A Pechère-Bertschi; L Perrin; P de Saussure; J J Widmann; E Giostra; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 2.  Rheumatoid factor, complement, and mixed cryoglobulinemia.

Authors:  Peter D Gorevic
Journal:  Clin Dev Immunol       Date:  2012-08-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.